1 out of 4 CBD Products is NOT Tested

for Microbial Content, Pesticides, or Heavy Metals 

The CBD industry’s peer-reviewed watchdog Leafreport.com recently undertook an comprehensive review of 2946 products from 136 brands to verify how many were being tested by third-party facilities for purity or potency. The report also released a list of the top ten most transparent brands.

“The CBD industry is still very unregulated,” said Shafir, the head of product at Leafreport. “There have been many cases of companies selling products that contain little to no CBD–that’s why third-party testing is so critical for brands in this industry.”

Pure, Clean CBD? It’s Unlikely: Only 13% of Brands Tested Almost All of Their Products for Purity

‘Clean’, ‘safe’, ‘natural’, or ‘pure’ CBD are pivotal selling points for many CBD brands. However, these buzz words are meaningless without the evidence to support such claims.

One of the key findings of the report was that only 13% of CBD companies tested almost all of their products for detectable levels of contaminants such as heavy metals, pesticides, or microbial content. But 25% didn’t test any of their products for purity at all.

“We were stunned to find that of the big-name brands we reviewed, one in four didn’t test any of their products for the presence of contaminants,” said Shafir. “It’s particularly concerning given that hemp, from which CBD is extracted, is a phyto-remedial plant that absorbs toxins and heavy metals from the soil”.

Do Most CBD Products Deliver the Promised Potency? Don’t Bet on It–84% Don’t Measure within the Acceptable Variance

Among other key findings exposed by the report were significant discrepancies between the product’s labelled potency compared with the contents of the bottle.

The concentration of CBD stated on a product label must match the concentration measured by the testing laboratory within a 10% variance, which means that a high-quality CBD product is expected to have CBD levels that are within 90–110% of what is advertised.

84% of the 2946 products tested were found to be outside the limits of acceptable variance. Leafreport also uncovered that only 42% of brands tested all their products for potency.

“The number of brands sidestepping third-party potency testing, or testing outside the allowable variance, is a genuine source of concern,” commented Shafir.

“Testing to ensure the potency of your product is accurate is a fundamental aspect of brand integrity–especially in the case of CBD products that are frequently used as medicine. Children diagnosed with rare forms of pediatric epilepsy use CBD to help control seizures, so it’s absolutely essential that their caregivers know what’s in the bottle to get dosage right.”

Less is More: Brands with Fewer than 8 Products are More Likely to Test for Both Purity and Potency

Another telling finding revealed by the report was that brands offering 7 products or less were more likely to test most of their products for both potency and purity, as opposed to brands with over 40 products. These results suggest that third-party testing may be more manageable, and financially practicable, for brands with fewer products.

It’s Time for CBD Brands to Level Up and Become More Accountable

Overall, the findings of the report indicate that vast discrepancies and unknowns characterize what consumers believe they are purchasing–and the actual contents of the CBD product.

“The excitement generated by CBD has led to the explosion of largely unregulated industry that must become more accountable to consumers,” reflected Shafir.

Transparency report summary

 

http://d1h.7b5.myftpupload.com/industry-insights/1-out-of-4-cbd-products-is-not-tested/?fbclid=IwAR0ih9_—UVMaK3xssQ6gXX17GwuP4fDbbXSRKDVZMz0krJ7UKUkkIpUf4

 

 

Recent Articles

Dr. Macias first fell in love with science while studying at Howard University, where she completed her undergraduate studies and later earned her PhD in cellular and molecular biology. While at Howard, she became especially interested in cancer research due to personal ties. Growing up in a Creole family and predominantly Black community in Louisiana, Dr. Macias watched many women around her battle breast cancer, so at Howard, she decided to focus her research on the BRCA1 gene.
It’s almost amazing that the same institutions that brought us the 2008 financial crisis have a problem with selling glass pipes. Almost. The truth is that an industry's past sins are only held against it when the money isn’t right. Big banks were willing to risk cratering the U.S. housing market because the profits were too good to ignore. But the cannabis industry rolls a different kind of paper, so instead of a slap on the wrist, it gets a surcharge.
Smokeshop and counterculture enthusiasts enjoy discovery as part of the experience. Customers enjoy browsing. When they walk into a shop, they don't simply grab a product and leave. They look for something new. This is the main reason flyers and posters still work. Smokeshops and dispensaries are highly visual environments. You want to see bold artwork, psychedelic graphics, and street-style posters that naturally capture attention.
The use of cannabis in professional sports has always been a controversial subject. While some are firm believers that all substances should be banned from professional sports altogether, most people aren’t thinking about cannabis when they’re discussing performance-enhancing drugs (PEDs). In fact, there have been countless cannabis users in the world of professional sports throughout the years; some of whom are more open about their love for the plant than others.
North Carolina might save us all. A new state bill may be the industry’s best option to save itself from demise when new federal cannabinoid bans take effect in November. And it could use your support.
Hemp is often considered for the things that it is not. It is not intoxicating, it is not illegal, and it is not marijuana. However, now we are seeing a focus back to what it can be. The plant is moving into the level of wine and chocolate and becoming a movement and a culture.
It’s been several months since President Donald Trump signed an executive order to reschedule cannabis from Schedule I to Schedule III within the Controlled Substances Act (CSA). On paper, the recent executive order, entitled “Increasing Medical Marijuana and Cannabidiol Research,” is a huge step in the right direction for cannabis smokers across the country.
For years, we’ve been told that this industry is the Wild West: a place where the only law amounts to whatever the guy with the gun says. But over the last 12 months, state governments have passed a spate of new regulations that promise to swap the relative lawlessness of poor enforcement of vague rules with real law and order.